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Cell membrane receptors rarely work on isolation, often they form oligomeric complexes
with other receptor molecules and they may directly interact with different proteins of the
signal transduction machinery. For a variety of reasons, rhodopsin-like class A G-protein-
coupled receptors (GPCRs) seem an exception to the general rule of receptor–receptor
direct interaction. In fact, controversy surrounds their potential to form homo- hetero-
dimers/oligomers with other class A GPCRs; in a sense, the field is going backward
instead of forward. This review focuses on the convergent, complementary and telling
evidence showing that homo- and heteromers of class A GPCRs exist in transfected
cells and, more importantly, in natural sources. It is time to decide between questioning
the occurrence of heteromers or, alternatively, facing the vast scientific and technical
challenges that class A receptor-dimer/oligomer existence pose to Pharmacology and
to Drug Discovery.
Keywords: dimerization, dopamine receptor, GPCR, homodimer, heteromer, ligands, mammalian receptor, signal
transduction taste receptor
INTRODUCTION
Historical views on any particular topic are both subjective and necessary. In the pre-G-protein-
coupled receptor (GPCR) dimer era, pharmacological approaches of a variety of receptors
attempted to know GPCR function while providing the tools for developing new drugs targeting
GPCRs. Upon cloning, the classical pharmacological approach was challenged by functional studies
in heterologous cells transfected with cDNAs coding for receptors. When the possibility of dimer
occurrence was first suggested (Fuxe et al., 1983; Fuxe and Agnati, 1985) and, afterward, proved
(vide infra), the previous working hypothesis and models were unsuitable to provide answers to
the new questions. Intriguingly, the field is entering now in an unfruitful controversy instead
of facing dimers to change the GPCR molecular physiology and pharmacological paradigms.
Around 10 years after the (Prinster et al., 2005) comprehensive review on “specificity and
functional significance” of GPCR hetero(di)merization and of the first IUPHAR recommendation
on recognition and nomenclature of GPCR Hets, there is a need to reinforce the relevance of GPCR
heteromerization (class A receptors included) for academic and for pharmaceutical purposes.
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Although, GPCR homomerization provides advantages
versus single/monomeric receptors (Banères and Parello, 2003;
Corriden et al., 2014; Gherbi et al., 2015; Marsango et al., 2015),
GPCR heteromerization gives added values for mammalians1,
namely signaling versatility and diversity. For instance, whereas
a dimer of a GPCR coupled to Gi would still be coupled to Gi,
a heteromer constituted by two different receptors may couple
to different signaling pathways than the individual receptors.
Heteromerization in any context, i.e., T cell receptors, taste
receptors, or adrenalin, dopamine, adenosine and opioid GPCRs,
among others, entail selective advantages. As an example,
receptor heteromers (Hets) are needed to taste many different
flavors. Should not class A GPCRs heterodimers exist to provide
a similar extra-added value (Franco, 2009)? One wonders
why evolution could skip this straightforward signal decoding
mechanism, but there is enough evidence to show that it is not
the case. An exhaustive account of the selective advantages of
class A GPCR heteromerization is out of the scope of the present
article. From our laboratory we would select the adenosine A1–
A2A receptor Het, which is a device able to sense the adenosine
concentration and respond via Gi at low concentrations and via
Gs at high concentrations (Ciruela et al., 2006; Ferré et al., 2007;
Cristóvão-Ferreira et al., 2013). From other laboratories it is
very difficult to choose but the coupling of the dopamine D1–D2
receptor Het to Gq (Rashid et al., 2007; So et al., 2007; Hasbi et al.,
2009; George et al., 2014) when individual D1 or D2 receptors
are coupled to, respectively, Gs or Gi, is worth mentioning. Also
relevant is the finding of opioid receptor Hets that explain the
strange pharmacology of opioid receptors and the atypical results
obtained by drugs selectively targeting opioid receptor Hets, and
that has helped to optimize the opioid receptor nomenclature
(Gomes et al., 2000; Portoghese and Lunzer, 2003; Bhushan
et al., 2004; Daniels et al., 2005; Waldhoer et al., 2005; van Rijn
et al., 2010; Yekkirala et al., 2010; Gupta et al., 2014). Those few
examples and the hundreds of already identified Hets contrast
with the existing controversy on class A GPCR heteromerization.
Here, we will first compare the little but convincig evidence for
taste receptor Hets with the similar but unconvincing evidence for
heteromerization of two class A receptors (dopamine D1 and D2).
Later the review selects a few Hets and a few techniques to build
up examples of the varied, complementary and overwhelming
evidence of class A GPCR heteromerization.
MONOMERIC AND DIMERIC TASTE
RECEPTORS versus EVIDENCE FOR
DOPAMINE D1/D2 RECEPTOR Hets
The three basic tastes, umami, sweet and bitter, are sensed
by two types of specialized GPCRs, taste T1 and T22. T1
and T2 receptors are similar to, respectively, class C and
1Actually it would be relevant to check whether heteromerization occurs in
invertebrates and/or in lower vertebrates. Finding any animal Kingdom in
which class A GPCR Hets do not occur would be extremely relevant to prove
heteromerization of class A receptors and to better understand the added value
of Hets.
2www.guidetopharmacology.org
class A GPCRs. IUPHAR indicates that taste T1 receptors are
obligate Hets: “T1R3 acts as an obligate partner in T1R1/T1R3
and T1R2/T1R3 heterodimers, which sense umami or sweet,
respectively. T1R1/T1R3 heterodimers respond to L-glutamic acid
and may be positively allosterically modulated by 5′-nucleoside
monophosphates, such as 5′-GMP [2]3. T1R2/T1R3 heterodimers
respond to sugars, such as sucrose, and artificial sweeteners,
such as saccharin (Nelson et al., 2001).” In this seminal
paper referenced by IUPHAR, Nelson et al. (2001) using an
heterologous expression system report “T1R2 and T1R3 combine
to function as a sweet receptor.” Few years later, Hets for two
class A dopamine receptors (D1 and D2) were identified using
a quite similar experimental approach: “When dopamine D1 and
D2 receptors were coactivated in D1-D2 receptor hetero-oligomeric
complexes, a novel phospholipase C-mediated calcium signal was
generated” (So et al., 2007). For both T1R1/R2/R3 and D1–D2
Hets, calcium mobilization was used as read-out, transfecting
an engineered G protein in the case of taste receptors, and
taking profit of endogenous Gq expressed in HEK-293T cells in
the case of dopamine receptors. In the report of taste receptor
heteromerization, transiently transfected cells were used, and in
the report of dopamine receptor heteromerization, cells stably
expressing D1 and D2 receptors were employed. Whereas taste
T1 and class C GPCRs are considered Hets, class A receptor
dimerization in general, or dopamine D1–D2 receptor Hets in
particular are questioned in articles with titles such as: “GPCR
dimers fall apart” (Lambert, 2010) or “Evidence against dopamine
D1/D2 receptor heteromers” (Frederick et al., 2015). Reinforcing
the idea of class A GPCR heteromerization is now due.
Class A taste T2 receptors are another example of the criteria
used to accept dimerization. Although T2 receptors are often
depicted as two molecules interacting together, IUPHAR does not
support the dimeric view of these receptors. The main reason
for such differential criteria is the big extracellular portion in
T1. In fact, the most important difference between class A and
C GPCRs is that the last ones have large extracellular agonist
binding domains that may dimerize even in the absence of the
rest of the receptor molecule (Kunishima et al., 2000; Romano
et al., 2001; Kawahara et al., 2012). In contrast, the extracellular
N-terminal domain of rhodopsin-like GPCRs is too short to be
relevant for GPCR dimer formation. Historically, the discovery
of class A GPCR dimers started by taking advantage of techniques
used in the Immunology field for detecting interactions between
membrane proteins, being the T-cell receptor one of the best
studied (Figure 1). In this sense, antibody generation and co-
immunoprecipitation constituted a revolution in Immunology
and served to build up a molecular framework to understand
antigen recognition and cell responses. Antibodies raised against
GPCRs served to identify GPCRs by immunoblotting, and to
label them in cells and tissues. They were also instrumental to
identify homo- and heterodimers by immunoblotting and co-
immunoprecipitation (Ciruela et al., 1995; Franco et al., 1996;
Ginés et al., 2000; Gomes et al., 2000) and, more recently,
3Apparently, the linked reference (Li et al., 2002: prostaglandin receptor EP2
mediates PGE2 stimulated hypercalcemia in mice in vivo) does not match the
information related to taste receptors.
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FIGURE 1 | Schematic representation of the T-cell receptor-CD3
complex. The heterocomplex is formed by variable TCR-α and TCR-β chains
coupled to three dimeric signaling transduction modules CD3δ/ε, CD3γ/ε and
CD3ζ/ζ or CD247. CD3, Cluster of differentiation 3; CD247, cluster of
differentiation 247 or CD3ζ/ζ; ITAM, immunoreceptor tyrosine-based activation
motif; TCR, T-cell receptor.
by proximity ligation assays (Borroto-Escuela et al., 2011,
2012). Other techniques that are not based on antigen-antibody
recognition have confirmed these early findings on GPCR homo-
and heteromerization.
THE CONTROVERSY SURROUNDING
RHODOPSIN-LIKE CLASS A
G-PROTEIN-COUPLED RECEPTOR
HETEROMERIZATION
The hypothesis of dimerization/oligomerization of GPCRs for
neurotransmitters was put forward by Fuxe et al. (1983, 1987).
However, technical difficulties prevented the discovery of GPCR
dimers until the end of the 20th Century. Apart from diverse
evidence on receptor homodimerization, and for demonstration
that heteromerization was needed for cell surface expression and
for GABAB receptor function (White et al., 1998), identification
of first class A heterodimers came when Gomes et al. (2000)
reported the first Het for two subtypes of opioid receptors µ and
δ and when Ginés et al. (2000) identified the first Het of two
receptors for two different neurotransmitter/neuromodulators,
namely the adenosine A1 and dopamine D1 receptor Het.
As of 2014 the number of interactions between GPCRs was
537 (Borroto-Escuela et al., 2014). Proved contradictory results
constitute approximately 1% of the total Hets, i.e., 5–10, and these
exceptions have been reported in a given model but not found
in a different model or using another assay type (Fuxe et al.,
2014). This very low percentage of inconsistencies substantiates
that GPCR and in particular class A GPCR receptor–receptor
interactions appear as a robust discovery.
According to the rules of http://www.merriam-webster.com,
the belief that GPCRs -or else- are monomers may be referred
to as: monomerism. The Whorton et al. (2007) report was
instrumental for a certain consolidation of this phenomenon.
The authors showed that, in an artificial system, monomeric β2-
adrenergic receptors may activate the coupled G protein. Such
article has been frequently used in reviews and in thematic
meetings to reinforce the idea that class A GPCRs should be
monomers. On the one hand, it is likely that the lipoprotein
particles used in the assays could not accommodate two GPCR
molecules together to study differential properties of monomers
versus homo- or hetero-dimers. On the other hand, an in vitro
demonstration cannot be used to be certain about receptor
operation in vivo. Neither the Whorton et al. (2007) data
may scientifically substantiate authors’ assertion “cooperativity
of agonist binding is due to G protein association to the receptor
monomer and not receptor oligomerization.” Cooperativity in the
binding of ligands to receptor monomers is an oxymoron since
this phenomenon requires a dimer or a trimer or a higher-
order macromolecule with more than one orthosteric site. In
what concerns cooperativity by class A GPCR homomers, two
reports using fluorescent ligands to adenosine A3 receptors in
transfected cells, a challenging technological approach and a
solid theoretical formulation and data analysis (May et al., 2011;
Corriden et al., 2014), constitute solid grounds to interpret
biphasic curves as cooperativity on ligand binding to orthosteric
centers in a receptor dimer. Data from radioligand binding
assays may provide not only evidence for homomer but for Het
formation (Birdsall, 2010). The reluctance to accept class A GPCR
dimers may be also challenged taking advantage of both structural
information and interpretation of pharmacological data from
similarly basic but powerful approaches.
ARE THERE GPCR MONOMERS?
STRUCTURAL DATA FAVORING CLASS A
GPCR HOMODIMERS
The word “monomer,” often used in the GPCR research field
is defined by [Encyclopædia Britannica, Inc.] as “a molecule
of any of a class of compounds, mostly organic, that can react
with other molecules to form very large molecules, or polymers.
The essential feature of a monomer is polyfunctionality, the
capacity to form chemical bonds to at least two other monomer
molecules. Bifunctional monomers can form only linear, chainlike
polymers, but monomers of higher functionality yield cross-
linked, network polymeric products.” On the one hand, this
definition of a monomer built on solid chemical knowledge
should be considered in the field. On the other hand, even
assuming that a given GPCR may act in “isolation” and far
from other GPCRs, they are not monomers as they interact,
at least, with heterotrimeric G proteins. Therefore, the real
issue is whether or not class A GPCRs may interact with other
class A GPCRs while they already interact with a whole bunch
of other proteins. Furthermore, the nomenclature for GPCRs
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is confusing; probably an appropriate definition of “GPCR
molecule” is needed.
The big N-terminal extracellular domain of class C receptors
allows formation of crystals constituted by dimers of the
extracellular domain; in contrast, the N-terminal domain of class
A is very short and unable to form such dimers. This difference
in the size of the N-terminal extracellular domain seems to be the
only reason that dopamine receptors may not form dimers and
that class A T2 taste receptors may not form dimers whereas class
C T1 taste receptors do. Due to the overwhelming evidence for
class A GPCR homo/heteromerization, it may well happen that
dimerization is guided by transmembrane domains and not by
extracellular domains. To our knowledge no study on the relative
positions of extracellular versus transmebrane domains has been
performed. In the absence of such studies, fixing the dimeric
structure of the extracellular domains does not provide any clue
on the position of the transmembrane domains of the interacting
receptors, i.e., useful information on the quaternary structure of
the overall class C GPCR dimer complexes is missing.
Difficulties arising from crystallization of membrane proteins
have been sorted out for GPCRs using an approach that, in brief,
consists of molecules containing transmembrane helices fused to
proteins such as T4 lysozyme or thermostabilized apocytochrome
b562, which favor crystal formation. Structures from X-ray
diffraction data usually assume a monomer as the basic unit.
Such interpretation was sanctioned by the finding that arrays of
rhodopsin itself in crystals was antiparallel to the plane of the
membrane (Edwards et al., 2004; Li et al., 2004), something that
is not seemingly physiological but that was not found in other
solved rhodopsin structures showing parallel arrangements (vide
infra).
Subsequent studies, however, have developed crystals in
which GPCR dimers exist in the correct -parallel- orientation.
The obligate interfaces occurring in 3D GPCR structures (see
Cordomí et al., 2015) may not reflect real inter-protomer
interfaces of a dimer in its native conformation in the
cell surface, but the finding of two neighbor molecules in
GPCR crystals compatible with the arrangements of dimers in
biological membranes should be considered as relevant. Different
transmembrane helices, often in a head-to-head interacting mode
(Cordomí et al., 2015) do participate in the parallel receptor
dimer arrangement in a variety of class A GPCR crystals, from
activated rhodopsin (Salom et al., 2006), to CXCR4 chemokine
(Wu et al., 2010) and κ- or µ-opioid receptors (Manglik et al.,
2012; Wu et al., 2012). Parallel association of receptors have also
been described in crystals of β2-adrenoceptors (Cherezov et al.,
2007). As Wu et al. (2012) pointed out: “While the existence of
GPCR dimers in vivo and their physiological relevance remain
highly debatable, several distinct potential dimer interfaces are
starting to emerge from crystallographic and biochemical studies.”
Noteworthy, µ-opioid receptor bound to a morphinan
antagonist crystalizes as a dimer with an interface containing
a four-helix bundle motif formed by transmembrane domains
5 and 6 (Manglik et al., 2012). Shortly afterward, the 3D
structure of ligand-free turkey β1-adrenergic receptors in a lipid
membrane-like environment exhibited oligomers constituted by
two alternating dimer interfaces, one involving transmembrane
helices 4 and 5 and the other engaging transmembrane helices
1 and 2 and the first extracellular loop (Whorton et al., 2013).
Last but not least, the seven transmembrane domain of the
smoothened SMO receptor crystalizes as a parallel dimer. Despite
its relatively small similarity with class A GPCRs, the SMO
receptor shows a high degree of spatial conservation of the
transmembrane bundle and, also, structural correspondences in
the intracellular domains with the solved class A GPCR structures
(Wang et al., 2013). These structural features in SMO and class
A receptors have led to the suggestion to translate the class A
numbering nomenclature (Ballesteros and Weinstein, 1995) to
class F GPCRs (Wang et al., 2013).
Lacking yet is any structural data concerning Hets. Precisely,
one of the challenges in the GPCR field is Het crystallization,
irrespective of whether Hets are constituted by class A or class
C receptors. In fact, class C heteromerization has a long way to
go; as earlier-mentioned it is not known whether dimerization
of the N-extracellular domain conditions the transmembrane
intra-dimer interactions. It is possible that the hinge between
the N-terminal and the first transmembrane domain loses its
conformational flexibility upon dimerization. In other words,
it is not known whether transmembrane domains may bring
two class C receptors together independently of N-terminal-
domain dimerization, i.e., may a given class C Hets have in the
membrane more than one quaternary structure? May different
dimer structures be established by simultaneously involving
either transmembrane regions or the N-terminal domains?
Actually, class C Hets raise more structure-related questions than
putative class A Hets.
G-PROTEIN-COUPLED RECEPTORS IN
HETEROLOGOUS SYSTEMS AND
KNOCKOUT MICE
Adrenalin receptors were, and still are, a reference in the GPCR
research field. Pioneering studies were centered on adrenergic
receptors in natural sources, e.g., isolated heart membranes,
but this methodology was almost completely displaced by work
in heterologous systems. In fact, COS- or CHO-transfected
cells expressing the GPCR have been widespread used to know
the whereabouts of these receptors and the scientific advance
has been paramount and deserving the 2012 Nobel Prize in
Chemistry, awarded to Drs Lefkowitz and Kobilka.
Identification of GPCR dimers occurred in parallel in
transfected cells and in samples from natural sources.
Biophysical-based methodologies such as fluorescence (FRET) or
bioluminescence (BRET) energy transfer have been instrumental
to show homo- or hetero-dimers in living transfected cells.
A combination of FRET and BRET [sequential resonance energy
transfer (SRET); Carriba et al., 2008] has allowed detection of
GPCR trimers, and a combination of BRET with molecular
complementation, using GPCRs fused to complementary
hemiproteins of donor/acceptor BRET pairs, permits detection
of tetramers (Cristóvão-Ferreira et al., 2013; Bonaventura
et al., 2015). One of the issues raised by monomerism is the
high-amount of receptors present in transfected cells that may
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“force” dimer, trimer, etc. formation. By the same token, it
could be argued that many of the relevant findings in the last
30 years should be questioned as they have been obtained in
heterologous systems overexpressing the receptors. What is
more relevant, membranes used in drug screening usually come
from GPCR-overexpressing transfected cells that likely express
dimer and higher-order structures, therefore, the screening is
to, at least, homodimers. Consequently, one may wonder why
tools available for receptor dimers, as the two-state dimer model
(Franco et al., 2005, 2006; Casadó et al., 2007, 2009a,b), are
not used for data analysis; it provides more robust parameters
than alternative models such as the two-independent site, which
assumes one high affinity and one low-affinity population
of monomeric receptors. More importantly, should not the
previous knowledge be revisited if, as monomerism predicts,
GPCRs in the heterologous systems are forced to express
dimers?
Remarkably, many of the studies describing dimers have
attempted and succeeded in proving their occurrence in
natural sources. The literature identifying and proving Hets in
natural sources is extensive and this review is not intended
to exhaustively address it. The occurrence of Hets in natural
sources, however, should be taken into account when analyzing
data from transgenic animals defective in a given GPCR.
GPCRs are somewhat promiscuous in their interaction with
other GPCRs4 (Borroto-Escuela et al., 2014). Therefore, any
particular phenotype in one of these knockout animals is
not simply due to the lack of the GPCR but to the lack
of the Hets in which the GPCR participates. In this context,
pharmacologists may stick to naïvely assign a phenotype to
the lack of a monomer or take the lead in searching the tools
needed to correlate a given phenotype with a particular receptor
Het.
DIMER-MEDIATED AGONIST AFFINITY
MODULATION AND
CROSS-ANTAGONISM
Activation of class A GPCRs results in signal transduction,
meaning that agonist binding to the GPCR induces
conformational changes that are transmitted toward the
interior of the cell. Data from radioligand binding assays have
confirmed one of the predictions of Het formation, namely the
agonist-induced changes of affinity upon binding of a second
agonist to the partner receptor in a receptor heterocomplex
(Birdsall, 2010). In some cases, such modulation may be of
physiological relevance as occurs in the serotonin 5HT2A
and metabotropic glutamatergic 2 receptors (González-Maeso
et al., 2008). In other cases the phenomenon may reflect dimer
formation but the change in affinity is too small to be operating
in vivo.
Agonist affinity cross-modulation suggests Het formation
but it may not reflect a direct receptor–receptor interaction.
As G proteins remain attached to GPCRs in the membrane
4www.gpcr-hetnet.com
preparations used for radioligand binding, agonist-induced
conformational changes in a G protein coupled to one GPCR
may indirectly affect a second receptor that is not directly
interacting with the first one. By contrast, antagonists and inverse
agonists are molecules that bind to GPCRs and inhibit agonist-
induced signaling. Very consistently, the selective antagonist of
a receptor blocks the signal transduction induced by the agonist
binding to the partner heteroreceptor. This counter intuitive
fact may be explained by heteromerization. The phenomenon
has been described in a variety of GPCR Hets such as
orexin/corticotropin-releasing factor receptor (Navarro et al.,
2015), dopamine D1/histamine H3 (Moreno et al., 2011) or
angiotensin II AT1/dopamine D2 (Martínez-Pinilla et al., 2015)
receptor Hets. The Ockham’s razor or law of parsimony states
“pluralitas non est ponenda sine necessitate.” Accordingly, if a
convoluted indirect mechanism is not necessary, the simplest
explanation is provided by a GPCR Het framework in which the
antagonist fixes a non-productive conformational state in one
receptor that also impedes the activation of the partner receptor
in the Het. Indeed, cross-antagonism should be considered as
a tool of heteromer identification. Usually, cross-antagonism is
first demonstrated in heterologous cells co-expressing the two
receptors and constitutes a so-called Het print. Subsequently,
dimer occurrence may be investigated on looking for the
Het print in samples from mammalian tissues/organs. GPCR-
induced activation of the MAP kinase pathway(s) is a successful
readout for detecting cross-antagonism, for instance in the
central nervous system, both in fresh slices from brain regions
and primary cultures of neurons or glia (Balenga et al., 2014;
Martínez-Pinilla et al., 2014, 2015).
BIVALENT PROBES
The affinity of a given agonist for a given GPCR may change if
the receptor is forming Hets (Ferré et al., 2009). Het-selective
ligands were then searched for both, detecting Hets in vivo
and as conceptually novel therapeutic tools. One example is 6′-
guanidinonaltrindole, a opioid-receptor-Het selective drug, that
in preclinical studies showed analgesia only if administered in the
parts on the central nervous system where δ–κ-opioid receptor
Hets are expressed. The result was also a proof-of-concept for
tissue-selective drug targeting (Waldhoer et al., 2005).
Another strategy of selectively targeting homo- or
heterodimers is to synthesize bivalent compounds able to
simultaneously bind the two receptors in a GPCR dimer. These
molecules consist of two agonist/antagonist moieties separated
by spacers of variable length. Therefore, two orthosteric sites may
be bridged by a bivalent ligand if the two pharmacophores are
appropriately designed. The capacity of simultaneous binding
to two different orthosteric sites is an added value that may
be used to detect receptor dimers (Figure 2). A very detailed
review on the various possibilities of bivalent ligands for the
characterization of GPCR dimers is provided by Hiller et al.
(2013). Certainly, emerging structural information will help
revisit data on bivalent compounds to be sure of whether
the linkers have the appropriate length to allow simultaneous
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FIGURE 2 | Scheme of the simultaneous binding of bivalent ligands with linkers of appropriate length to two receptors in a GPCR dimer. The
agonist/antagonist moieties of the bivalent ligand are selective for their respective receptors (orange for GPCR-I, green for GPCR-II) and are linked by an spacer.
(A) Binding to two equal GPCRs forming an homodimer. (B) Binding to two different GPCRs forming an heterodimer. A full account of the possibilities of binding of
bivalent ligands to GPCRs is provided by Brogi et al. (2014).
binding to the two receptors in a given homo- or heterodimer
(see Glass et al., 2016).
Synthesis of bivalent ligands for GPCRs was performed in
the pioneering report of Halazy et al. (1996), years before
GPCR heterodimerization was reported. The authors concluded
that their results support: “. . .the hypothesis that the important
increase in potency of the serotonin dimers can be attributed
to the presence of two serotonin pharmacophores in the same
molecule.” Binding of those molecules to one orthosteric site
cannot provide any increase in affinity or potency but dimers
were not yet seriously considered at that time. It should be
also pointed out that as early as in 1982 dimeric peptide
enkephalins were synthesized and Shimohigashi et al. (1982)
proved their interaction with two δ- but not with two µ-opioid
receptors. To explain their results authors took advantage
of another phenomenon that, by the way, may occur upon
agonist activation, namely receptor clustering (Franco et al.,
1996). As dimers for opioid receptors were not yet described,
authors assumed that bivalent ligands were simultaneously acting
in two close receptors within receptor clusters. Qualitatively
similar results were obtained by Carrithers and Lerner (1996)
that found bivalent ligands for alpha-melanocyte stimulating
hormone receptors more potent than monovalents. Rationale
for the study was that “multivalency can increase the apparent
affinity of a ligand for its binding site” but the authors aimed at
designing bivalent ligands “to bind to two adjacent receptor sites.”
Multivalence of ligands together with dimer occurrence do fit
with these pioneering results.
Russo et al. (2007) designed bivalents ligands that were able
to bind, in transfected cells, to serotonin 5-HT4 constitutive
receptor dimers identified by Berthouze et al. (2005). To our
knowledge these compounds were not used to address the
occurrence of direct 5-HT4 receptor–receptor interactions in
natural sources. The differential binding to human dopamine
D2 receptor of bivalent and monovalent ligands also suggested
the occurrence of homodimers in transfected cells (Kühhorn
et al., 2011a,c). As the theory of ligand binding to receptors
would predict, the Hill coefficient of competition curves using a
radiolabeled antagonist, [3H]spiperone, was 2 for (homo)bivalent
and 1 for monovalent molecules (Kuhhorn et al., 2011b).
In Portoghese’s laboratory, the bivalent drug approach was
successfully used in vitro -in living cells- and in natural sources,
but also in behavioral models. Few years after the reporting of
the first class A GPCR Hets, bivalent ligands containing δ- and
κ-opioid antagonist moieties, provided evidence in the spinal
cord of Hets formed by δ-κ-opioid receptors (Bhushan et al.,
2004). Remarkably, these Hets explain the atypical pharmacology
found for opioid GPCR subtypes in some areas of the central
nervous system (Daniels et al., 2005), thus suggesting the
occurrence of these receptor Hets in natural sources.
Also consistent with in vivo occurrence of µ-opioid/
chemokine 5 receptor Hets, selective Het targeting may
significantly reduce neuropathic and inflammatory pain (Akgün
et al., 2013; Smeester et al., 2014). Although, the therapeutic
use of bivalents to combat pain is limited due to the
low chances of efficient crossing the blood brain barrier,
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these results are impotant to confirm Hets occurrence in vivo.
Performing radioligand binding experiments in samples from
tissues, and comparing competition curves of bi- and monovalent
drugs could indeed prove or disprove the existence of dimers
in mammals. In summary, heterobivalent ligands, i.e., molecules
having two different moieties with a linker of appropriate length,
are ad hoc probes for detecting GPCR Hets in natural sources.
In a detailed and careful study, Soriano et al. (2009)
designed, synthesized and tested bivalent ligands containing both
adenosine receptor agonist and dopamine receptor antagonist
pharmacophores. Molecules with the appropriate spacer length,
which was compatible with simultaneous binding to the
two receptors, bound (in co-transfected cells) dopamine D2
and adenosine A2A receptors with higher affinity than their
monovalent counterparts. This finding in cells coexpressing
the two receptors was similarly detected in membranes from
brain striatum. Those adenosine-dopamine bivalents did not
bind with higher affinity to membranes expressing only one
of the receptors. Modeling studies indicated that appropriate
linker lengths were consistent with simultaneous binding to
D2 and adenosine A2A receptor dimers. More importantly,
the results from competition assays using specific radioligands
(for adenosine or for dopamine receptors) can only be
explained if there is simultaneous binding to dimers. Basic
pharmacology indicates that simultaneous binding of bivalents
to two binding sites, should be characterized by higher affinity
than the monovalent control compounds. In fact, binding
of one moiety to one binding site increases the effective
local concentration available to the binding site in a partner
receptor.
In summary, despite the field seems not yet mature to fully
accept class A GPCR homo/heteromerization, data have been
stubborn on providing evidence of the phenomenon. The models
used have been very diverse and the techniques have been
from co-immunoprecipitation all the way to powerful energy
transfer in vitro and ex vivo assays and in vivo transactivation
using transgenic mice (Rivero-Müller et al., 2010; Jonas et al.,
2013; Grzesik et al., 2014). Class A receptor complexes have
also been visualized in tissues by means of atomic force
microcopy (Fotiadis et al., 2006; Cordomí and Perez, 2009),
confocal fluorescence resonance energy transfer (So et al.,
2007; Albizu et al., 2010; Perreault et al., 2010; Verma et al.,
2010). Moreover, their occurrence, deduced from the avidity of
peptides derived from class A GPCRs primary structure to bind
together, has been detected by definitive methods5 such as mass
spectrometry (Ciruela et al., 2004; Navarro et al., 2010), not to
mention the positive results from surface plasmon resonance
or recently-developed imaging techniques (e.g., fluorescence
cross-correlation spectroscopy) able to detect dimer/oligomer-
containing single particles.
AUTHOR CONTRIBUTIONS
RF: Contacting the Editor and contributing to the writing. JL:
Discussing the sections, correcting, and contributing to the
writing. GN: Contributing to the writing and searching for
some specific references. EM-P: Contributing to the writing and
preparing figures.
ACKNOWLEDGMENTS
This work was supported by grants SAF2012-39875-C02-01,
BFU2012-37907, and BFU2015-64405-R –including FEDER-
from the Spanish Ministry of Economy and Competitiveness
(MINECO) and by grants 201413-30 (to RF) and 201413-31 (to
JL) from the Fundació la Marató de TV3.
5 Definitive methods (Uriano and Gravatt, 1977) “are based on a valid and well-
described theoretical foundation, which has been experimentally validated so that
the reported results have negligible systematic errors and have high levels of
precision.”
REFERENCES
Akgün, E., Javed, M. I., Lunzer, M. M., Smeester, B. A., Beitz, A. J., and
Portoghese, P. S. (2013). Ligands that interact with putative MOR-mGluR5
heteromer in mice with inflammatory pain produce potent antinociception.
Proc. Natl. Acad. Sci. U.S.A. 110, 11595–11599. doi: 10.1073/pnas.1305
461110
Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., et al. (2010).
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.
Nat. Chem. Biol. 6, 587–594. doi: 10.1038/nchembio.396
Balenga, N. A., Martínez-Pinilla, E., Kargl, J., Schröder, R., Peinhaupt, M.,
Platzer, W., et al. (2014). Heteromerization of GPR55 and cannabinoid
CB2 receptors modulates signaling. Br. J. Pharmacol. 171, 1–64. doi:
10.1111/bph.12850
Ballesteros, J. A., and Weinstein, H. (1995). Integrated methods for the
construction of three-dimensional models and computational probing of
structure-function relations in G protein-coupled receptors. Methods Neurosci.
25, 366–428. doi: 10.1016/S1043-9471(05)80049-7
Banères, J.-L., and Parello, J. (2003). Structure-based analysis of GPCR function:
evidence for a novel pentameric assembly between the dimeric leukotriene
B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329, 815–829. doi:
10.1016/S0022-2836(03)00439-X
Berthouze, M., Ayoub, M., Russo, O., Rivail, L., Sicsic, S., Fischmeister, R., et al.
(2005). Constitutive dimerization of human serotonin 5-HT4 receptors in living
cells. FEBS Lett. 579, 2973–2980. doi: 10.1016/j.febslet.2005.04.040
Bhushan, R. G., Sharma, S. K., Xie, Z., Daniels, D. J., and Portoghese, P. S. (2004).
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are
organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes.
Selective targeting of delta-kappa heterodimers. J. Med. Chem. 47, 2969–2972.
doi: 10.1021/jm0342358
Birdsall, N. J. M. (2010). Class a GPCR heterodimers: evidence from
binding studies. Trends Pharmacol. Sci. 31, 499–508. doi: 10.1016/j.tips.2010.
08.003
Bonaventura, J., Navarro, G., Casadó-Anguera, V., Azdad, K., Rea, W., Moreno, E.,
et al. (2015). Allosteric interactions between agonists and antagonists within
the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc. Natl.
Acad. Sci. U.S.A. 112, E3609–E3618. doi: 10.1073/pnas.1507704112
Borroto-Escuela, D. O., Brito, I., Romero-Fernandez, W., Di Palma, M., Oflijan, J.,
Skieterska, K., et al. (2014). The G protein-coupled receptor heterodimer
network (GPCR-HetNet) and its hub components. Int. J. Mol. Sci. 15, 8570–
8590. doi: 10.3390/ijms15058570
Borroto-Escuela, D. O., Romero-Fernandez, W., Mudó, G., Pérez-Alea, M.,
Ciruela, F., Tarakanov, A. O., et al. (2012). Fibroblast growth factor
receptor 1- 5-hydroxytryptamine 1A heteroreceptor complexes and their
Frontiers in Pharmacology | www.frontiersin.org 7 March 2016 | Volume 7 | Article 76
fphar-07-00076 March 31, 2016 Time: 15:2 # 8
Franco et al. Class A GPCR Dimers
enhancement of hippocampal plasticity. Biol. Psychiatry 71, 84–91. doi:
10.1016/j.biopsych.2011.09.012
Borroto-Escuela, D. O., Van Craenenbroeck, K., Romero-Fernandez, W.,
Guidolin, D., Woods, A. S., Rivera, A., et al. (2011). Dopamine D2 and D4
receptor heteromerization and its allosteric receptor–receptor interactions.
Biochem. Biophys. Res. Commun. 404, 928–934. doi: 10.1016/j.bbrc.2010.
12.083
Brogi, S., Tafi, A., Désaubry, L., and Nebigil, C. G. (2014). Discovery of GPCR
ligands for probing signal transduction pathways. Front. Pharmacol. 5:255. doi:
10.3389/fphar.2014.00255
Carriba, P., Navarro, G., Ciruela, F., Ferré, S., Casadó, V., Agnati, L., et al.
(2008). Detection of heteromerization of more than two proteins by sequential
BRET-FRET. Nat. Methods 5, 727–733. doi: 10.1038/nmeth.1229
Carrithers, M. D., and Lerner, M. R. (1996). Synthesis and characterization of
bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol.
3, 537–542. doi: 10.1016/S1074-5521(96)90144-1
Casadó, V., Cortés, A., Ciruela, F., Mallol, J., Ferré, S., Lluis, C., et al. (2007).
Old and new ways to calculate the affinity of agonists and antagonists
interacting with G-protein-coupled monomeric and dimeric receptors: the
receptor-dimer cooperativity index. Pharmacol. Ther. 116, 343–354. doi:
10.1016/j.pharmthera.2007.05.010
Casadó, V., Cortés, A., Mallol, J., Pérez-Capote, K., Ferré, S., Lluis, C., et al.
(2009a). GPCR homomers and heteromers: a better choice as targets for drug
development than GPCR monomers? Pharmacol. Ther. 124, 248–257. doi:
10.1016/j.pharmthera.2009.07.005
Casadó, V., Ferrada, C., Bonaventura, J., Gracia, E., Mallol, J., Canela, E. I.,
et al. (2009b). Useful pharmacological parameters for G-protein-coupled
receptor homodimers obtained from competition experiments. Agonist-
antagonist binding modulation. Biochem. Pharmacol. 78, 1456–1463. doi:
10.1016/j.bcp.2009.07.012
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S.,
Kobilka, T. S., et al. (2007). High-resolution crystal structure of an engineered
human b2 -adrenergic G protein-coupled receptor. Science 318, 1258–1265. doi:
10.1126/science.1150577
Ciruela, F., Burgueño, J., Casadó, V., Canals, M., Marcellino, D., Goldberg, S. R.,
et al. (2004). Combining mass spectrometry and pull-down techniques for
the study of receptor heteromerization. Direct epitope-epitope electrostatic
interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem.
76, 5354–5363. doi: 10.1021/ac049295f
Ciruela, F., Casado, V., Mallol, J., Canela, E. I., Lluis, C., and Franco, R.
(1995). Immunological identification of A1 adenosine receptors in brain cortex.
J. Neurosci. Res. 42, 818–828. doi: 10.1002/jnr.490420610
Ciruela, F., Casadó, V., Rodrigues, R. J., Luján, R., Burgueño, J., Canals, M.,
et al. (2006). Presynaptic control of striatal glutamatergic neurotransmission
by adenosine A1-A2A receptor heteromers. J. Neurosci. 26, 2080–2087. doi:
10.1523/JNEUROSCI.3574-05.2006
Cordomí, A., Navarro, G., Aymerich, M. S., and Franco, R. (2015). Structures
for G-protein-coupled receptor tetramers in complex with G proteins. Trends
Biochem. Sci. 40, 548–551. doi: 10.1016/j.tibs.2015.07.007
Cordomí, A., and Perez, J. J. (2009). Structural rearrangements of rhodopsin
subunits in a dimer complex: a molecular dynamics simulation study.
J. Biomol. Struct. Dyn. 27, 127–147. doi: 10.1080/07391102.2009.
10507303
Corriden, R., Kilpatrick, L. E., Kellam, B., Briddon, S. J., and Hill, S. J.
(2014). Kinetic analysis of antagonist-occupied adenosine-A3 receptors within
membrane microdomains of individual cells provides evidence of receptor
dimerization and allosterism. FASEB J. 28, 4211–4222. doi: 10.1096/fj.13-
247270
Cristóvão-Ferreira, S., Navarro, G., Brugarolas, M., Pérez-Capote, K., Vaz, S. H.,
Fattorini, G., et al. (2013). A1R-A2AR heteromers coupled to Gs and G i/0
proteins modulate GABA transport into astrocytes. Purinergic Signal 9, 433–
449. doi: 10.1007/s11302-013-9364-5
Daniels, D. J., Kulkarni, A., Xie, Z., Bhushan, R. G., and Portoghese, P. S. (2005).
A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist
pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J. Med.
Chem. 48, 1713–1716. doi: 10.1021/jm034234f
Edwards, P. C., Li, J., Burghammer, M., Hugh McDowell, J., Villa, C., Hargrave,
P. A., et al. (2004). Crystals of native and modified bovine rhodopsins
and their heavy atom derivatives. J. Mol. Biol. 343, 1439–1450. doi:
10.1016/j.jmb.2004.08.089
Ferré, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., et al. (2009).
Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol.
5, 131–134. doi: 10.1038/nchembio0309-131
Ferré, S., Ciruela, F., Quiroz, C., Luján, R., Popoli, P., Cunha, R. A., et al. (2007).
Adenosine receptor heteromers and their integrative role in striatal function.
Sci. World J. 7, 74–85. doi: 10.1100/tsw.2007.211
Fotiadis, D., Jastrzebska, B., Philippsen, A., Müller, D. J., Palczewski, K., and
Engel, A. (2006). Structure of the rhodopsin dimer: a working model for
G-protein-coupled receptors. Curr. Opin. Struct. Biol. 16, 252–259. doi:
10.1016/j.sbi.2006.03.013
Franco, R. (2009). G-protein-coupled receptor heteromers or how neurons can
display differently flavoured patterns in response to the same neurotransmitter.
Br. J. Pharmacol. 158, 23–31. doi: 10.1111/j.1476-5381.2009.00181.x
Franco, R., Casadó, V., Ciruela, F., Mallol, J., Lluis, C., and Canela, E. I.
(1996). The cluster-arranged cooperative model: a model that accounts for the
kinetics of binding to A1 adenosine receptors. Biochemistry 35, 3007–3015. doi:
10.1021/bi952415g
Franco, R., Casadó, V., Mallol, J., Ferrada, C., Ferré, S., Fuxe, K., et al.
(2006). The two-state dimer receptor model: a general model for
receptor dimers. Mol. Pharmacol. 69, 1905–1912. doi: 10.1124/mol.105.
020685
Franco, R., Casadó, V., Mallol, J., Ferré, S., Fuxe, K., Cortés, A., et al. (2005). Dimer-
based model for heptaspanning membrane receptors. Trends Biochem. Sci. 30,
360–366. doi: 10.1016/j.tibs.2005.05.010
Frederick, A. L., Yano, H., Trifilieff, P., Vishwasrao, H. D., Biezonski, D.,
Mészáros, J., et al. (2015). Evidence against dopamine D1/D2 receptor
heteromers. Mol. Psychiatry 20, 1373–1385. doi: 10.1038/mp.2014.166
Fuxe, K., and Agnati, L. F. (1985). Receptor-receptor interactions in the central
nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5,
441–482. doi: 10.1002/med.2610050404
Fuxe, K., Agnati, L. F., Benfenati, F., Celani, M., Zini, I., Zoli, M., et al.
(1983). Evidence for the existence of receptor–receptor interactions in the
central nervous system. Studies on the regulation of monoamine receptors by
neuropeptides. J. Neural Transm. Suppl. 18, 165–179.
Fuxe, K., Härfstrand, A., Agnati, L. F., Kalia, M., Fredholm, B., Svensson, T.,
et al. (1987). Central catecholamine-neuropeptide Y interactions at the pre-
and postsynaptic level in cardiovascular centers. J. Cardiovasc. Pharmacol. 1(10
Suppl. ), S1–S13. doi: 10.1097/00005344-198709002-00001
Fuxe, K., Tarakanov, A., Romero Fernandez, W., Ferraro, L., Tanganelli, S.,
Filip, M., et al. (2014). Diversity and bias through receptorâ€“receptor
interactions in GPCR heteroreceptor complexes. focus on examples from
dopamine D2 receptor heteromerization. Front. Endocrinol. (Lausanne) 5:71.
doi: 10.3389/fendo.2014.00071
George, S. R., Kern, A., Smith, R. G., and Franco, R. (2014). Dopamine receptor
heteromeric complexes and their emerging functions. Prog. Brain Res. 211,
183–200. doi: 10.1016/B978-0-444-63425-2.00008-8
Gherbi, K., May, L. T., Baker, J. G., Briddon, S. J., and Hill, S. J. (2015).
Negative cooperativity across β1-adrenoceptor homodimers provides insights
into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor
binding conformation. FASEB J. 29, 2859–2871. doi: 10.1096/fj.14-
265199
Ginés, S., Hillion, J., Torvinen, M., Le Crom, S., Casadó, V., Canela, E. I.,
et al. (2000). Dopamine D1 and adenosine A1 receptors form functionally
interacting heteromeric complexes. Proc. Natl. Acad. Sci. U.S.A. 97, 8606–8611.
doi: 10.1073/pnas.150241097
Glass, M., Govindpani, K., Furkert, D. P., Hurst, D. P., Reggio, P. H., and
Flanagan, J. U. (2016). One for the price of two. . .are bivalent ligands
targeting cannabinoid receptor dimers capable of simultaneously binding to
both receptors? Trends Pharmacol. Sci. doi: 10.1016/j.tips.2016.01.010 [Epub
ahead of print].
Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000).
Heterodimerization of mu and delta opioid receptors: a role in opiate synergy.
J. Neurosci. 20:RC110.
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-
Giménez, J. F., et al. (2008). Identification of a serotonin/glutamate receptor
complex implicated in psychosis. Nature 452, 93–97. doi: 10.1038/nature06612
Frontiers in Pharmacology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 76
fphar-07-00076 March 31, 2016 Time: 15:2 # 9
Franco et al. Class A GPCR Dimers
Grzesik, P., Teichmann, A., Furkert, J., Rutz, C., Wiesner, B., Kleinau, G.,
et al. (2014). Differences between lutropin-mediated and choriogonadotropin-
mediated receptor activation. FEBS J. 281, 1479–1492. doi: 10.1111/febs.12718
Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., et al. (2014).
Increased abundance of opioid receptor heteromers after chronic morphine
administration. Sci. Signal 3:ra54. doi: 10.1126/scisignal.2000807
Halazy, S., Perez, M., Fourrier, C., Pallard, I., Pauwels, P. J., Palmier, C., et al. (1996).
Serotonin dimers: application of the bivalent ligand approach to the design of
new potent and selective 5-HT(1B/1D) agonists. J. Med. Chem. 39, 4920–4927.
doi: 10.1021/jm960552l
Hasbi, A., Fan, T., Alijaniaram, M., Nguyen, T., Perreault, M. L., O’Dowd,
B. F., et al. (2009). Calcium signaling cascade links dopamine D1-D2 receptor
heteromer to striatal BDNF production and neuronal growth. Proc. Natl. Acad.
Sci. U.S.A. 106, 21377–21382. doi: 10.1073/pnas.0903676106
Hiller, C., Kühhorn, J., and Gmeiner, P. (2013). Class A G-protein-coupled receptor
(GPCR) dimers and bivalent ligands. J. Med. Chem. 56, 6542–6559. doi:
10.1021/jm4004335
Jonas, K. C., Rivero-Müller, A., Huhtaniemi, I. T., and Hanyaloglu, A. C. (2013). G
protein-coupled receptor transactivation: from molecules to mice. Methods Cell
Biol. 117, 433–450. doi: 10.1016/B978-0-12-408143-7.00023-2
Kawahara, K., Suenobu, M., Yoshida, A., Koga, K., Hyodo, A., Ohtsuka, H., et al.
(2012). Intracerebral microinjection of interleukin-4/interleukin-13 reduces
β-amyloid accumulation in the ipsilateral side and improves cognitive deficits
in young amyloid precursor protein 23 mice. Neuroscience 207, 243–260. doi:
10.1016/j.neuroscience.2012.01.049
Kühhorn, J., Götz, A., Hübner, H., Thompson, D., Whistler, J., and Gmeiner, P.
(2011a). Development of a bivalent dopamine D2 receptor agonist. J. Med.
Chem. 54, 7911–7919. doi: 10.1021/jm2009919
Kühhorn, J., Hubner, H., and Gmeiner, P. (2011b). Bivalent dopamine D2 receptor
ligands: synthesis and binding properties. J. Med. Chem. 54, 4896–4903. doi:
10.1021/jm2004859
Kühhorn, J., Hübner, H., Gmeiner, P., Kuhhorn, J., Hubner, H., and Gmeiner, P.
(2011c). Bivalent dopamine D2 receptor ligands: synthesis and binding
properties. J. Med. Chem. 54, 4896–4903. doi: 10.1021/jm2004859
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., et al.
(2000). Structural basis of glutamate recognition by a dimeric metabotropic
glutamate receptor. Nature 407, 971–977. doi: 10.1038/35039564
Lambert, N. A. (2010). GPCR dimers fall apart. Sci. Signal. 3:e12. doi:
10.1126/scisignal.3115pe12
Li, J., Edwards, P. C., Burghammer, M., Villa, C., and Schertler, G. F. X. (2004).
Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343,
1409–1438. doi: 10.1016/j.jmb.2004.08.090
Li, X., Tomita, M., Pilbeam, C. C., Breyer, R. M., and Raisz, L. G. (2002).
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice
in vivo. Prostaglandins Other Lipid Mediat. 67, 173–180. doi: 10.1016/S0090-
6980(01)00186-1
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara,
R. K., et al. (2012). Crystal structure of the µ-opioid receptor bound to a
morphinan antagonist. Nature 485, 321–326. doi: 10.1038/nature10954
Marsango, S., Caltabiano, G., Pou, C., Varela Liste, M. J., and Milligan, G.
(2015). Analysis of human dopamine D3 receptor quaternary
structure. J. Biol. Chem. 290, 15146–15162. doi: 10.1074/jbc.M114.
630681
Martínez-Pinilla, E., Reyes-Resina, I., Oñatibia-Astibia, A., Zamarbide, M.,
Ricobaraza, A., Navarro, G., et al. (2014). CB1 and GPR55 receptors are co-
expressed and form heteromers in rat and monkey striatum. Exp. Neurol. 261,
44–52. doi: 10.1016/j.expneurol.2014.06.017
Martínez-Pinilla, E., Rodríguez-Pérez, A. I., Navarro, G., Aguinaga, D., Moreno, E.,
Lanciego, J. L., et al. (2015). Dopamine D2 and angiotensin II type 1 receptors
form functional heteromers in rat striatum. Biochem. Pharmacol. 96, 131–142.
doi: 10.1016/j.bcp.2015.05.006
May, L. T., Bridge, L. J., Stoddart, L. A., Briddon, S. J., and Hill, S. J. (2011).
Allosteric interactions across native adenosine-A3 receptor homodimers:
quantification using single-cell ligand-binding kinetics. FASEB J. 25, 3465–3476.
doi: 10.1096/fj.11-186296
Moreno, E., Hoffmann, H., Gonzalez-Sepúlveda, M., Navarro, G., Casadó, V.,
Cortés, A., et al. (2011). Dopamine D1-histamine H3 receptor heteromers
provide a selective link to MAPK signaling in GABAergic neurons of the direct
striatal pathway. J. Biol. Chem. 286, 5846–5854. doi: 10.1074/jbc.M110.161489
Navarro, G., Ferre, S., Cordomi, A., Moreno, E., Mallol, J., Casado, V., et al.
(2010). Interactions between intracellular domains as key determinants of the
quaternary structure and function of receptor heteromers. J. Biol. Chem. 285,
27346–27359. doi: 10.1074/jbc.M110.115634
Navarro, G., Quiroz, C., Moreno-Delgado, D., Sierakowiak, A., McDowell, K.,
Moreno, E., et al. (2015). Orexin-corticotropin-releasing factor receptor
heteromers in the ventral tegmental area as targets for cocaine. J. Neurosci. 35,
6639–6653. doi: 10.1523/JNEUROSCI.4364-14.2015
Nelson, G., Hoon, M. A., Chandrashekar, J., Zhang, Y., Ryba, N. J. P., and
Zuker, C. S. (2001). Mammalian sweet taste receptors. Cell 106, 381–390. doi:
10.1016/S0092-8674(01)00451-2
Perreault, M. L., Hasbi, A., Alijaniaram, M., Fan, T., Varghese, G., Fletcher,
P. J., et al. (2010). The dopamine D1-D2 receptor heteromer localizes
in dynorphin/enkephalin neurons: increased high affinity state following
amphetamine and in schizophrenia. J. Biol. Chem. 285, 36625–36634. doi:
10.1074/jbc.M110.159954
Portoghese, P. S., and Lunzer, M. M. (2003). Identity of the putative delta1-opioid
receptor as a delta-kappa heteromer in the mouse spinal cord. Eur. J. Pharmacol.
467, 233–234. doi: 10.1016/S0014-2999(03)01599-1
Prinster, S. C., Hague, C., and Hall, R. A. (2005). Heterodimerization of g protein-
coupled receptors: specificity and functional significance. Pharmacol. Rev. 57,
289–298. doi: 10.1124/pr.57.3.1
Rashid, A. J., So, C. H., Kong, M. M. C., Furtak, T., El-Ghundi, M., Cheng, R., et al.
(2007). D1-D2 dopamine receptor heterooligomers with unique pharmacology
are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci.
U.S.A. 104, 654–659. doi: 10.1073/pnas.0604049104
Rivero-Müller, A., Chou, Y.-Y., Ji, I., Lajic, S., Hanyaloglu, A. C., Jonas, K., et al.
(2010). Rescue of defective G protein-coupled receptor function in vivo by
intermolecular cooperation. Proc. Natl. Acad. Sci. U.S.A. 107, 2319–2324. doi:
10.1073/pnas.0906695106
Romano, C., Miller, J. K., Hyrc, K., Dikranian, S., Mennerick, S., Takeuchi, Y.,
et al. (2001). Covalent and non covalent interactions mediate metabotropic
glutamate receptor mGlu5 dimerization. Mol. Pharmacol. 59, 46–53.
Russo, O., Berthouze, M., Giner, M., Soulier, J.-L., Rivail, L., Sicsic, S., et al. (2007).
Synthesis of specific bivalent probes that functionally interact with 5-HT (4)
receptor dimers. J. Med. Chem. 50, 4482–4492. doi: 10.1021/jm070552t
Salom, D., Lodowski, D. T., Stenkamp, R. E., Le Trong, I., Golczak, M.,
Jastrzebska, B., et al. (2006). Crystal structure of a photoactivated deprotonated
intermediate of rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 103, 16123–16128. doi:
10.1073/pnas.0608022103
Shimohigashi, Y., Costa, T., Chen, H. C., and Rodbard, D. (1982). Dimeric
tetrapeptide enkephalins display extraordinary selectivity for the delta opiate
receptor. Nature 297, 333–335. doi: 10.1038/297333a0
Smeester, B. A., Lunzer, M. M., Akgün, E., Beitz, A. J., and Portoghese,
P. S. (2014). Targeting putative mu opioid/metabotropic glutamate receptor-
5 heteromers produces potent antinociception in a chronic murine bone
cancer model. Eur. J. Pharmacol. 743, 48–52. doi: 10.1016/j.ejphar.2014.
09.008
So, C. H., Verma, V., O’Dowd, B. F., and George, S. R. (2007). Desensitization of
the dopamine D1 and D2 receptor hetero-oligomer mediated calcium signal
by agonist occupancy of either receptor. Mol. Pharmacol. 72, 450–462. doi:
10.1124/mol.107.034884
Soriano, A., Ventura, R., Molero, A., Hoen, R., Casadó, V., Cortés, A., et al. (2009).
Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent
ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med.
Chem. 52, 5590–5602. doi: 10.1021/jm900298c
Uriano, G., and Gravatt, C. (1977). The role of reference materials and reference
methods in chemical analysis. Crit. Rev. Anal. Chem. 6, 361–376. doi:
10.1080/10408347708085697
van Rijn, R. M., Whistler, J. L., and Waldhoer, M. (2010). Opioid-receptor-
heteromer-specific trafficking and pharmacology. Curr. Opin. Pharmacol. 10,
73–79. doi: 10.1016/j.coph.2009.09.007
Verma, V., Hasbi, A., O’Dowd, B. F., and George, S. R. (2010). Dopamine D1-D2
receptor Heteromer-mediated calcium release is desensitized by D1 receptor
occupancy with or without signal activation: dual functional regulation by
Frontiers in Pharmacology | www.frontiersin.org 9 March 2016 | Volume 7 | Article 76
fphar-07-00076 March 31, 2016 Time: 15:2 # 10
Franco et al. Class A GPCR Dimers
G protein-coupled receptor kinase 2. J. Biol. Chem. 285, 35092–35103. doi:
10.1074/jbc.M109.088625
Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E.,
et al. (2005). A heterodimer-selective agonist shows in vivo relevance of G
protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 102, 9050–9055.
doi: 10.1073/pnas.0501112102
Wang, C., Wu, H., Katritch, V., Han, G. W., Huang, X.-P., Liu, W., et al. (2013).
Structure of the human smoothened receptor bound to an antitumour agent.
Nature 497, 338–343. doi: 10.1038/nature12167
White, J. H., Wise, A., Main, M. J., Green, A., Fraser, N. J., Disney, G. H.,
et al. (1998). Heterodimerization is required for the formation of a functional
GABA(B) receptor. Nature 396, 679–682. doi: 10.1038/25354
Whorton, M. R., Bokoch, M. P., Rasmussen, S. G. F., Huang, B., Zare, R. N.,
Kobilka, B., et al. (2007). A monomeric G protein-coupled receptor isolated in
a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl.
Acad. Sci. U.S.A. 104, 7682–7687. doi: 10.1073/pnas.0611448104
Whorton, M. R., Bokoch, M. P., Rasmussen, S. G. F., Huang, B., Zare, R. N.,
Kobilka, B., et al. (2013). Crystal structure of oligomeric β1-adrenergic G
protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20,
419–425. doi: 10.1038/nsmb.2504
Wu, B., Chien, E. Y. T., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., et al.
(2010). Structures of the CXCR4 chemokine GPCR with small-molecule and
cyclic peptide antagonists. Science 330, 1066–1071. doi: 10.1126/science.11
94396
Wu, H., Wacker, D., Katritch, V., Mileni, M., Han, G. W., Liu, W., et al. (2012).
Structure of the human kappa opioid receptor in complex with JDTic. Nature
485, 327–332. doi: 10.1038/nature10939
Yekkirala, A. S., Kalyuzhny, A. E., and Portoghese, P. S. (2010). Standard
opioid agonists activate heteromeric opioid receptors: evidence for
morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective
µ-δ agonists. ACS Chem. Neurosci. 1, 146–154. doi: 10.1021/cn90
00236
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Franco, Martínez-Pinilla, Lanciego and Navarro. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 10 March 2016 | Volume 7 | Article 76
